Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%

The Next Crossroad of SaaS: Vertical or Horizontal?

The SaaS (Software as a Service) industry has developed in China over nearly three decades. From horizontal SaaS formats to Vertical SaaS, great changes have taken place. Now the SaaS industry has entered a boom stage.

Fremont Micro Devices Raises CNY 500 Million from Pre-IPO Funding Round

Fremont Micro Devices is a high-tech enterprise focusing on developing non-volatile memory products and high-efficiency power management solutions. It officially announced the completion of a CNY 500 million (USD 70.3 million) Pre-IPO financing round, led by Huaxun Found.

15 Companies to Watch in September 2022- Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in September 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the startups operate.

Insight Lifetech Completes Series D+ Equity Round

Insight Lifetech, a high-tech company dedicated to providing innovative solutions for cardiovascular disease precision intervention, will continue to provide more innovative products and services and provide changes to precision diagnosis and treatment of cardiovascular diseases.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?